Celgene 'aims to be at forefront of real-world data use,' in bid to boost Otezla impact
In an oral presentation to be given at the annual meeting of the European League Against Rheumatism (EULAR), US-based Celgene (Nasdaq: CELG) will present a post hoc analysis of data from the PALACE trial program that suggest new, previously uncaptured benefits of Otezla (apremilast) against psoriatic arthritis.
Celgene has focused on all six domains of the disease – peripheral arthritis, enthesitis, dactylitis, axial disease, skin disease and nail disease, in an attempt to tease out specific treatment benefits.
The firm’s data show patients achieved significant reductions in swollen joint count (58%), tender joint count (42%) and Physician’s Global Assessment of Disease Activity score (49%) after 104 weeks of treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze